

REMARKS

Claims 1-6 have been examined on their merits, and are all the claims presently pending in the application.

The Patent Office objects to the Abstract and specification due to the usage of the phrase “(PCR; MCR)”. The term “PCR” stands for peak cell rate and the term “MCR” stands for minimum cell rate. *See, e.g.*, U.S. Application Serial No. 09/392,336, which was incorporated by reference; page 9, lines 8-29 of the instant application. These two terms are typical traffic contract parameters. Applicant herein editorially amends the Abstract to remove the reference callouts “(PCR; MCR)”. No new matter has been added to the Abstract. In addition, Applicant herein editorially amends the written disclosure to correct spelling and typographical errors, and to update the status of the related application. The phrase “(PCR; MCR)” was not present in the written disclosure. In response to the Patent Office’s objection to the written disclosure and drawing, Applicant has editorially amended the written disclosure to recite “FIG. 1” instead of “Figure”. No new matter has been added to the Abstract or the written disclosure. Applicant submits that the Patent Office’s objections have been overcome, and respectfully request withdrawal of same.

The Patent Office objects to claims 1 and 6 due to the usage of the phrase “(PCR; MCR)”. The term “PCR” stands for peak cell rate and the term “MCR” stands for minimum cell rate. *See, e.g.*, U.S. Application Serial No. 09/392,336, which was incorporated by reference; page 9, lines 8-29 of the instant application. These two terms are typical traffic contract parameters. Their inclusion in claims 1 and 6 was merely as reference callouts, and was not

AMENDMENT UNDER 37 C.F.R. § 1.111
U.S. APPLN. NO. 09/691,049
ATTORNEY DOCKET NO. Q61398

intended in any manner to constitute a recitation of either claim. Applicant has amended claims 1 and 6 to remove the phrase "(PCR; MCR)" and submits that the Patent Office's objection has been overcome. Applicant respectfully requests withdrawal of the Patent Office's objection to claims 1 and 6.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER


Paul J. Wilson
Registration No. 45,879

Date: August 5, 2004